1. Home
  2. MDXH vs NSPR Comparison

MDXH vs NSPR Comparison

Compare MDXH & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • NSPR
  • Stock Information
  • Founded
  • MDXH 2003
  • NSPR 2005
  • Country
  • MDXH Belgium
  • NSPR United States
  • Employees
  • MDXH N/A
  • NSPR N/A
  • Industry
  • MDXH
  • NSPR Medical/Dental Instruments
  • Sector
  • MDXH
  • NSPR Health Care
  • Exchange
  • MDXH Nasdaq
  • NSPR Nasdaq
  • Market Cap
  • MDXH 84.6M
  • NSPR 79.7M
  • IPO Year
  • MDXH 2021
  • NSPR N/A
  • Fundamental
  • Price
  • MDXH $2.09
  • NSPR $2.19
  • Analyst Decision
  • MDXH Buy
  • NSPR Strong Buy
  • Analyst Count
  • MDXH 1
  • NSPR 2
  • Target Price
  • MDXH $6.00
  • NSPR $4.50
  • AVG Volume (30 Days)
  • MDXH 75.5K
  • NSPR 50.0K
  • Earning Date
  • MDXH 05-14-2025
  • NSPR 05-09-2025
  • Dividend Yield
  • MDXH N/A
  • NSPR N/A
  • EPS Growth
  • MDXH N/A
  • NSPR N/A
  • EPS
  • MDXH N/A
  • NSPR N/A
  • Revenue
  • MDXH $94,507,000.00
  • NSPR $7,027,000.00
  • Revenue This Year
  • MDXH $23.38
  • NSPR $28.93
  • Revenue Next Year
  • MDXH $16.84
  • NSPR $172.18
  • P/E Ratio
  • MDXH N/A
  • NSPR N/A
  • Revenue Growth
  • MDXH 25.46
  • NSPR 8.49
  • 52 Week Low
  • MDXH $1.35
  • NSPR $2.07
  • 52 Week High
  • MDXH $3.50
  • NSPR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 74.52
  • NSPR 31.62
  • Support Level
  • MDXH $1.67
  • NSPR $2.31
  • Resistance Level
  • MDXH $1.99
  • NSPR $2.69
  • Average True Range (ATR)
  • MDXH 0.13
  • NSPR 0.17
  • MACD
  • MDXH 0.02
  • NSPR -0.03
  • Stochastic Oscillator
  • MDXH 97.67
  • NSPR 5.51

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: